Stock EQL EQL PHARMA AB
Add to a list
To use this feature you must be a member
Log inSign up

Ratings EQL Pharma AB NORDIC GROWTH MARKET

Equities

EQL

SE0005497732

End-of-day quote NORDIC GROWTH MARKET
Other stock markets
 06:00:00 2024-07-04 pm EDT 		5-day change 1st Jan Change
60.8 SEK -1.62% Intraday chart for EQL Pharma AB +8.57% +82.04%

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The prospective high growth for the next fiscal years is among the main assets of the company
  • The company's earnings per share (EPS) are expected to grow significantly over the next few years according to the consensus of analysts covering the stock.
  • Over the last twelve months, the sales forecast has been frequently revised upwards.
  • Growth remains a strong point in this company. In their sales forecast, analysts sound optimistic with regard to sales prospects.

Weaknesses

  • With an enterprise value anticipated at 3.98 times the sales for the current fiscal year, the company turns out to be overvalued.
  • In relation to the value of its tangible assets, the company's valuation appears relatively high.
  • The company is highly valued given the cash flows generated by its activity.
  • The three month average target prices set by analysts do not offer high potential in comparison with the current prices.
  • Over the past four months, analysts' average price target has been revised downwards significantly.

Ratings chart - Surperformance

Sector: Drug Retailers

1st Jan change Capi. Investor Rating ESG Refinitiv
EQL PHARMA AB Stock EQL Pharma AB
+82.04% 155M -
WALGREENS BOOTS ALLIANCE, INC. Stock Walgreens Boots Alliance, Inc.
-55.53% 10.1B
B-
JD HEALTH INTERNATIONAL INC. Stock JD Health International Inc.
-46.55% 8.81B
B
ALIBABA HEALTH INFORMATION TECHNOLOGY LIMITED Stock Alibaba Health Information Technology Limited
-25.71% 6.65B
B
MATSUKIYOCOCOKARA & CO. Stock MatsukiyoCocokara & Co.
-4.16% 6.45B
C+
CORPORATIVO FRAGUA, S.A.B. DE C.V. Stock Corporativo Fragua, S.A.B. de C.V.
+97.00% 5.35B
C
NAHDI MEDICAL COMPANY Stock Nahdi Medical Company
-2.92% 4.63B
D-
CLICKS GROUP LIMITED Stock Clicks Group Limited
+8.08% 4.6B
B
YIFENG PHARMACY CHAIN CO., LTD. Stock Yifeng Pharmacy Chain Co., Ltd.
-33.29% 3.79B
C
REDCARE PHARMACY NV Stock Redcare Pharmacy NV
+6.38% 3.13B
B
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
-

Business Predictability

Analyst Coverage
Divergence of Estimates
-
Divergence of analysts' opinions
-
Divergence of Target Price
-
Earnings quality
-
  1. Stock Market
  2. Equities
  3. EQL Stock
  4. EQL Stock
  5. Ratings EQL Pharma AB